Alnodesertib

Alnodesertib
Clinical data
Other namesGTPL13731; BDBM570448; ART-0380; IACS-030380
Identifiers
  • 4-[4-[(cyclopropyl-methyl-oxo-λ6-sulfanylidene)amino]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC18H24N6O2S
Molar mass388.49 g·mol−1
3D model (JSmol)
  • C[C@@H]1COCCN1C2=NC(=NC(=C2)N=[S@](=O)(C)C3CC3)C4=CC(=NC=C4)N
  • InChI=InChI=1S/C18H24N6O2S/c1-12-11-26-8-7-24(12)17-10-16(23-27(2,25)14-3-4-14)21-18(22-17)13-5-6-20-15(19)9-13/h5-6,9-10,12,14H,3-4,7-8,11H2,1-2H3,(H2,19,20)/t12-,27+/m1/s1
  • Key:JHPDHYAMSPMBIF-MUDIAHQHSA-N

Alnodesertib is an investigational new drug that is being developed by Artios Pharma for the treatment of solid tumours. It is an ataxia telangiectasia and Rad3 related (ATR) protein inhibitor.

Clinical trials

Alnodesertib is currently in clinical trials for solid tumors. Another study was terminated "not for reasons affecting the benefit-risk balance".

References

  1. 1 2 "Alnodesertib - Artios Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ "WHO proposed international nonproprietary names list" (PDF). World Health Organization. Retrieved 3 July 2026.
  3. ↑ Qin S, An J, Qiao W, Zhichao X, Siyao T, Seo G, et al. (June 2026). "Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors". Biomedicine & Pharmacotherapy. 201 119670. doi:10.1016/j.biopha.2026.119670. PMID 42314345.
  4. ↑ Kciuk M, Wanke K, Marciniak B, Kołat D, Aleksandrowicz M, Mujwar S, et al. (January 2026). "Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature". International Journal of Molecular Sciences. 27 (3): 1152. doi:10.3390/ijms27031152. PMC 12898043. PMID 41683580.
  5. ↑ Clinical trial number NCT04657068 NCT04657068 for "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov
  6. ↑ Clinical trial number NCT05798611 for "Study of ART0380 in Patients With Biologically Selected Solid Tumors" at ClinicalTrials.gov